Dear readers, here are a couple of papers published in the previous months, with a few lines explaining why these papers appear worth signalling over the many others that had not aroused a particular attention.
For this month the papers are:
1) 2013 ACC/AHA guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association. Stone NJ, Robinson J. Lichtentein AH, et al; Circulation. 2013, Nov 12. [Epub ahead of print].
These 2013 Guidelines appears after 11 years since the previous ones and definitely change the rules of cholesterol treatment. The 2013 Guidelines have already raised several criticisms and comments. The 2002 ones were strongly supporting statine therapy to individuals affected only by high level of cholesterol. Now the risk and the results have been recalculated: the result is that we must treat patients only, not levels.
2) Jugular venous reflux and white matter abnormalities in Alzheimer’s Disease: a pilot study. Chung CP, Beggs C., Wang PN et al; J Alzheimers Dis; 2013, Nov 8 [Epub ahead of print].
This study (on 12 Alzheimer’s disease patients, 24 mild cognitive impaired patients and 17 controls) report in AD patients jugular veins findings quite similar to those that prompted Zamboni and colleagues to propose chronic cerebrospinal venous insufficiency (CCVI) as a resolving therapy in multiple sclerosis. Comments?